A chromogenic assay for use as a screening test for the identification of antithrombin deficiency is described. The heparin concentration and the incubation time in the assay were optimised specifically to permit the detection of heparin binding defects of antithrombin.
Methods
Heparin (5000 IU/ml) was purchased from Leo Laboratories; Bovine thrombin (1000 IU/ml) was purchased from Diagnostic Reagents Ltd, Thame, England; Chromozym TH (1-9 mM) was purchased from Boehringer Mannheim.
Control plasma was purchased from Immuno AG, Vienna (R78, 100% activity). The Third British Standard (antithrombin activity-88%) was also used as a control. Normal plasma was collected from a pool of 20 healthy volunteers and assigned a value of 100% activity. Plasma containing the antithrombin variant, antithrombin Basel, was collected from a patient undergoing investigation for recurrent venous thrombosis. The defect (41 Pro-Leu) had been confirmed by both DNA and protein sequencing. Plasma containing the antithrombin variant, antithrombin Rouen I (47 Arg-His), was a gift from Dr Y Borg. Plasma from patients with known antithrombin variants was collected into trisodium citrate (9 parts blood: 1 part citrate), separated, and stored at -80°C until assayed.
Excess thrombin is incubated with a dilute plasma sample containing an unknown concentration of antithrombin in the presence of heparin. The residual thrombin activity, measured with a chromogenic substrate, is inversely proportional to the antithrombin activity. There are two variables which affect the sensitivity of the assay-namely, the incubation time and the heparin concentration.
OPTIMISING CONDITIONS FOR THE DETECTION OF HEPARIN BINDING DEFECTS OF ANTITHROMBIN
Antithrombin activity was measured in normal plasma, the plasma containing the antithrombin variants, and the control plasmas.
Diluted plasma (100 p1) (1 in 50 in 0-9 M NaCl) was incubated for 30 seconds, 60 seconds, 90 seconds, and 120 seconds with 100 pl TRIS buffer (50 mM TRIS, 100 mM NaCl, pH containing 60 IU/l of heparin and 4 IU/ml bovine thrombin. Chromogenic substrate (chromozym TH) (50 ,ul) was added to the reaction mixture and the absorbance was read over 30 seconds at 405 nm. All reactions were performed on the ACL300 (Instrumentation Lab). A standard curve was established using normal plasma at three dilutions.
The assay using heparin was performed as described above except that the incubation time was fixed at 60 seconds and various heparin concentrations were used (0, 20, 60, 120, 1000 IU/1).
Results

INCUBATION TIME
Plasma containing normal antithrombin inhibited thrombin maximally within 30 seconds, so the residual thrombin activity was unaffected by further prolongation of the incubation time ( fig IA) . The plasma containing the heparin antithrombin showed less inhibition. The difference between normal antithrombin and the variants of antithrombin was most pronounced between 60 IU/l and 250 IU/l of heparin (fig 2A) , as the heparin concentration increased the difference became less pronounced. Figure 2B shows the assay with a short incubation time and significantly higher activity (a rise of at least 20%) in the assay with a longer incubation time. Plasma containing other antithrombin defects will give consistently low activity results with both the short and long incubation times.
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